<\/p>\n
Melorise<\/strong> je meloxicam tablet<\/strong> dostupn\u00fd v 7.5 mg and 15 mg<\/strong> strengths. Meloxicam is a preferential COX-2 NSAID<\/strong> with a long half-life (~20 hours) that permits denn\u00ed d\u00e1vkov\u00e1n\u00ed<\/strong>. It is used for osteoarthritis (7.5 mg\/day), rheumatoid arthritis, and ankylosing spondylitis (15 mg\/day), and provides strong anti-inflammatory action with a modestly gentler GI profile than non-selective NSAIDs. Take with food.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Melorise<\/strong> je peror\u00e1ln\u00ed tableta meloxicam<\/strong>, an NSAID in the oxicam class with preferential activity against COX-2. At therapeutic doses (7.5–15 mg\/day), meloxicam inhibits COX-2 (the inflammation-driving isoform) substantially more than COX-1 (the stomach-protective isoform), giving a modest but real reduction in gastric-ulcer risk compared with classical non-selective NSAIDs like diclofenac, ibuprofen, and naproxen.<\/p>\n Meloxicam has a long plasma half-life of approximately 20 hours, which allows simple denn\u00ed d\u00e1vkov\u00e1n\u00ed<\/strong> and steady 24-hour anti-inflammatory cover — a practical advantage in chronic inflammatory arthritis where adherence matters.<\/p>\n Meloxicam is a preferential COX-2 inhibitor. At therapeutic doses it shows roughly a 10-fold selectivity for COX-2 over COX-1, placing it between the non-selective NSAIDs (ibuprofen, diclofenac, naproxen) and the highly selective coxibs (celecoxib, etoricoxib). Clinical trials and meta-analyses confirm a modest but real reduction in GI ulcer and bleed rate compared with non-selective NSAIDs, while pain-relief efficacy is comparable.<\/p>\n Swallow whole with water. Always take with food. If you miss a dose, take it as soon as you remember unless the next dose is due within 8 hours — then skip.<\/p>\n GI, cardiovascular, and renal safety.<\/strong> Meloxicam carries all the standard NSAID risks (GI ulcer, heart attack, stroke, acute kidney injury, raised blood pressure). Use at the lowest effective dose for the shortest clinically reasonable time. Consider adding a proton pump inhibitor for courses longer than 2–4 weeks. Patients with established cardiovascular disease should discuss with their doctor before starting.<\/p>\n<\/div>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Melorise Used For?<\/h2>\n
\n
How Does Meloxicam Work?<\/h2>\n
Melorise Dosing<\/h2>\n
\n
Who Should Not Take Melorise?<\/h2>\n
\n
Side Effects of Melorise<\/h2>\n
\n
Melorise vs Other NSAIDs<\/h2>\n